Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-11-02
Ethical does not pass the values gate
Price16.90 USD
Fair value14.72
Ethical score70.0/100
Value readOvervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-25Read Markup15.72+7.5% to today ✓Accumulation gives way to Markup after a 6% rise in 7 days
2026-10-18Read Accumulation14.87+13.7% to today ✓Markup gives way to Accumulation after a 6% rise in 7 days
2026-10-11Read Markup14.07+20.1% to today ✓Distribution gives way to Markup after a 5% rise in 2 weeks
2026-09-24Read Distribution13.36+26.5% to today Markup gives way to Distribution after a 23% rise in 12 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
AvePoint, Inc. holds its Markup at $16.90. The statistical read favours the buyers, held for 22 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 22 days
Price at the screen
$16.90
Valuation
52.81 trailing · 33.97 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.09
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.26%
Below 33%
Interest-bearing debt is just 1.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
73.39%
Below 49%
Money owed to the company is 73.4% of assets, above the 49% limit.
Fail
Revenue purity
1.09%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
AvePoint,'s business is fine, but its receivables are about 73% of its assets, well over the ~49% line, so it does not pass on the financial screens.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVPT's ethical verdict changes
Today AVPT does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 4 Nov 2026: it trades above our $14.72 fair value estimate, 22.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 14.8% above the base estimate.
Where our models see it going: fair-value estimate $14.72, with a range of $12.60 to $16.92, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cloud data tools rarely clear a fair price
Picture a company whose software organises the endless files that pile up inside Microsoft 365 and SharePoint. AvePoint does that job, yet it trades at 26.6 times forward earnings for 26 percent revenue growth and an 11 percent profit margin. With the shares only 6 percent below our fair value, the margin of safety is wafer thin and the opportunity rating sits at none.
The numbers show steady progress, a 12 percent return on equity and an ethical screen that passes cleanly, but the valuation already prices in the growth analysts expect. Thirteen firms carry a buy rating and a 15 dollar median target; nothing here suggests the market has overlooked a bargain.
High multiples leave little room for the usual software hiccups of slower renewals or rising competition. When growth cools even a notch the rating can compress quickly. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVPT trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$16.44-3.8%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$17.09+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$17.09+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$17.09-0.6%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$17.20+0.0%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$17.20+0.0%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$17.20+9.4%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 36% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup · changed$15.72+5.7%Entry 10
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter.
2026-10-11Markup · changed$14.07+5.3%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 43%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (13 analysts) rates it none, with a mean price target of $16. Insiders have been net sellers over the past quarter.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
